In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
Researchers from Kyushu University have developed an innovative computational method, called ddHodge, that can reconstruct ...
It has been claimed that because most of our DNA is active, it must be important, but now human-plant hybrid cells have been ...
Red Cat Holdings, Inc.'s NDAA-compliant, American-made drones enable expansion into commercial markets. Learn more about RCAT ...
Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...
The global photovoltaic adhesive film market, projected to reach $45.3 billion by 2031, is undergoing a dramatic shift as ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 5 undervalued stocks in the Chemicals industry for Tuesday, December 23, 2025. Let’s take a ...
Background PD-1 blockade has emerged as a promising approach for functional cure of chronic hepatitis B (CHB). Objective This study aimed to evaluate the safety profile of anti-PD-1 antibody (αPD-1), ...
From vitamin C to your microbiome and mindset, the latest science of immunity is often counterintuitive. Here's how to give ...
The region helped invent cell and gene therapy. Now, there’s an opportunity to reengineer it so more people can actually access it, a life sciences leader writes.
Memorial Sloan Kettering Cancer Center researchers continued to make strides against cancer in 2025. Learn about some of their top discoveries.
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback